)
Shares of Suven Life Sciences has soared 19% to Rs 296, also its new high on BSE, after the biopharmaceutical company said it has secured patents in the US and New Zealand.
“The company secured patents in USA and New Zealand to one of their New Chemical Entity (NCE) for CNS therapy through new mechanism of action – H3 Inverse agonist and these patents are valid until 2030 and 2031 respectively,” Suven Life Sciences said in news release.
These therapeutic agents are useful in the treatment of cognitive impairment associated with neurodegenerative disorders, the company said.
With these new patents, Suven has a total of 20 granted patents from US and 23 granted patents from New Zealand.
The stock opened at Rs 250 and touched a low of Rs 243 on BSE in early morning trade. The counter has seen huge trading volumes with a combined 8.77 million shares changed hands till 1511 hours against an average sub 2 million shares that were traded daily in past two-weeks on BSE and NSE.
“The company secured patents in USA and New Zealand to one of their New Chemical Entity (NCE) for CNS therapy through new mechanism of action – H3 Inverse agonist and these patents are valid until 2030 and 2031 respectively,” Suven Life Sciences said in news release.
These therapeutic agents are useful in the treatment of cognitive impairment associated with neurodegenerative disorders, the company said.
With these new patents, Suven has a total of 20 granted patents from US and 23 granted patents from New Zealand.
The stock opened at Rs 250 and touched a low of Rs 243 on BSE in early morning trade. The counter has seen huge trading volumes with a combined 8.77 million shares changed hands till 1511 hours against an average sub 2 million shares that were traded daily in past two-weeks on BSE and NSE.
